Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
Clin Colorectal Cancer. 2018 Mar;17(1):e1-e12. doi: 10.1016/j.clcc.2017.06.007. Epub 2017 Jun 24.
Decision-making regarding palliative treatment for patients with metastatic colorectal cancer (mCRC) is complex and comprises numerous decisions. Decision-making should be guided by the premise of maintaining and/or improving patients' quality of life, by patient preference, and by the trade-off between treatment benefits and harm. Decision support systems (DSSs) for clinicians (eg, nomograms) can assist in this process. The present systematic review aimed to provide a comprehensive overview of the available DSSs for incurable mCRC and to assess their clinical usefulness.
A systematic literature search was performed in PubMed, Embase, and the Cochrane Library. We extracted information on the DSS characteristics and their discriminatory ability, calibration, and user-friendliness.
From 5205 studies, we identified 14 DSSs for decisions regarding palliative resection of the primary tumor (n = 3), radiotherapy for metastases (n = 2), treatment type (invasive vs. symptomatic only; n = 7), and selection of chemotherapy (n = 2). The predictors varied greatly among the DSSs, and only 1 DSS incorporated a genetic marker (ie, UGT1A1). None of the DSSs included > 1 treatment option, nor did any DSS present estimates of treatment benefits and harms. Five tools had not been externally validated, two had only been validated in < 35 patients, and the rest had only been validated in populations similar to the population used for their development. Discriminatory accuracy was generally moderate to poor. Calibration measures were only reported for 2 tools.
A limited number of DSSs are available to support palliative treatment decisions for patients with mCRC, and the evidence regarding their discriminatory ability and calibration is too limited to recommend their use. New DSSs comparing multiple treatment options and presenting both treatment benefits and harms are needed.
针对转移性结直肠癌(mCRC)患者的姑息治疗决策较为复杂,包含诸多决策。决策应基于维持和/或提高患者生活质量、患者偏好,以及权衡治疗获益与危害的前提。临床医生的决策支持系统(DSS,如列线图)可辅助这一过程。本系统评价旨在全面概述现有的不可治愈 mCRC 姑息治疗决策支持系统,并评估其临床实用性。
在 PubMed、Embase 和 Cochrane 图书馆进行了系统文献检索。我们提取了 DSS 特征及其区分能力、校准和用户友好性的信息。
从 5205 项研究中,我们确定了 14 项针对姑息性切除原发肿瘤(n=3)、转移灶放疗(n=2)、治疗类型(侵袭性与仅对症治疗;n=7)和化疗选择(n=2)的 DSS。这些 DSS 的预测因素差异较大,仅有 1 个 DSS 纳入了遗传标志物(即 UGT1A1)。没有一个 DSS 纳入了>1 种治疗方案,也没有任何 DSS 提供治疗获益和危害的估计。有 5 个工具尚未进行外部验证,有 2 个仅在<35 例患者中进行了验证,其余工具仅在与开发人群相似的人群中进行了验证。区分准确性通常为中等至较差。仅有 2 个工具报告了校准指标。
目前仅存在少数支持 mCRC 患者姑息治疗决策的 DSS,关于其区分能力和校准的证据还非常有限,无法推荐使用。需要开发新的 DSS 来比较多种治疗方案,并同时提供治疗获益和危害的信息。